254 related articles for article (PubMed ID: 36424577)
1. Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?
Shayan S; Arashkia A; Azadmanesh K
Cancer Cell Int; 2022 Nov; 22(1):370. PubMed ID: 36424577
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy: Challenges and solutions.
Goradel NH; Baker AT; Arashkia A; Ebrahimi N; Ghorghanlu S; Negahdari B
Curr Probl Cancer; 2021 Feb; 45(1):100639. PubMed ID: 32828575
[TBL] [Abstract][Full Text] [Related]
3. Employing tumor hypoxia for oncolytic therapy in breast cancer.
Chun YS; Adusumilli PS; Fong Y
J Mammary Gland Biol Neoplasia; 2005 Oct; 10(4):311-8. PubMed ID: 16826462
[TBL] [Abstract][Full Text] [Related]
4. Enhancing oncolytic virotherapy: Observations from a Voronoi Cell-Based model.
Jenner AL; Frascoli F; Coster ACF; Kim PS
J Theor Biol; 2020 Jan; 485():110052. PubMed ID: 31626813
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.
Marchica V; Costa F; Donofrio G; Giuliani N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668361
[TBL] [Abstract][Full Text] [Related]
7. Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia.
Shayan S; Arashkia A; Bahramali G; Abdoli A; Nosrati MSS; Azadmanesh K
Cancer Cell Int; 2022 Apr; 22(1):164. PubMed ID: 35477503
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
[TBL] [Abstract][Full Text] [Related]
9. Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?
Naumenko VA; Stepanenko AA; Lipatova AV; Vishnevskiy DA; Chekhonin VP
Mol Ther Oncolytics; 2022 Mar; 24():663-682. PubMed ID: 35284629
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virotherapy and the Tumor Microenvironment.
Berkey SE; Thorne SH; Bartlett DL
Adv Exp Med Biol; 2017; 1036():157-172. PubMed ID: 29275471
[TBL] [Abstract][Full Text] [Related]
11. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
Yokoda R; Nagalo BM; Vernon B; Oklu R; Albadawi H; DeLeon TT; Zhou Y; Egan JB; Duda DG; Borad MJ
Oncolytic Virother; 2017; 6():39-49. PubMed ID: 29184854
[TBL] [Abstract][Full Text] [Related]
13. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia enhances the replication of oncolytic herpes simplex virus.
Aghi MK; Liu TC; Rabkin S; Martuza RL
Mol Ther; 2009 Jan; 17(1):51-6. PubMed ID: 18957963
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
Tassone E; Muscolini M; van Montfoort N; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
[TBL] [Abstract][Full Text] [Related]
17. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
18. Syncytia Formation in Oncolytic Virotherapy.
Burton C; Bartee E
Mol Ther Oncolytics; 2019 Dec; 15():131-139. PubMed ID: 31890866
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
Zhang Y; Li Y; Chen K; Qian L; Wang P
J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
[TBL] [Abstract][Full Text] [Related]
20. Anticancer efficiency of reovirus in normoxia and hypoxia.
Figová K; Hraběta J; Eckschlager T
Folia Biol (Praha); 2013; 59(2):68-75. PubMed ID: 23746172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
